Johns Hopkins University
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
Inclusion Criteria: * Patients with relapsing forms of MS. * Age between 18 and 65 years old (inclusive). * On treatment with standard interval ocrelizumab for at least one year. * Eligible and willing to continue treatment with ocrelizumab or ublituximab. * The presence of wearing off phenomena, defined as either worsening in any Neuro-QoL sleep disturbance, fatigue, depression, upper and lower extremity scores (moving from a lower category of symptom severity to a higher category, based on previously defined cutoff scores), a worsening of Neuro-QoL score of 10 points (which equals 1 SD) or…
Ublituzimab will be administered via IV infusion as specified throughout the study period.
Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
Arctuva estimate
Verify or correct the compensation shown for this listing.